European Companies Search Engine
EU funding (€10.7M): IMAGING FOR PATIENT BENEFIT IN ARTHRITIS Hor1 Nov 2024 EU Research and Innovation programme "Horizon"
Overview
Text
IMAGING FOR PATIENT BENEFIT IN ARTHRITIS
Patients at risk or diagnosed with arthritis are constantly assessed by innovative imaging techniques to document the onset or progression of their disease. However, despite their impressive abundance and resolution, these images lack the analysis and interpretation tools necessary to deliver unbiased and precise diagnosis, monitoring and prognosis to the patients. Additionally, some key advanced imaging methodologies such as ultrasound are hardly accessible to most of patients, urging improvements of more accessible imaging methods. The AutoPiX project is an ambitious international multi-stakeholder effort led jointly and synergistically by academic and industry partners to achieve breakthroughs in both the applicability and harnessing of imaging technologies for the benefit of patients by creating new powerful analysis and decision tools. We will first generate tools to transform unstructured images into quantitative biomarkers using artificial intelligence (AI) and machine learning (ML) models, and validate them clinically for their diagnosis, monitoring and prognosis power. This will considerably increase the utility of imaging biomarkers for arthritis and bring them to the same level as laboratory biomarkers. In parallel we will develop accessible imaging strategies such as remote monitoring and robotic-powered point-of-care ultrasound exams for patients to mitigate the often-observed shortage of qualified personnel in real world settings. To achieve this, we will improve the precision and interpretability of these methods and further validate them with clinical, molecular and histological analyses. Our consortium is built on multi-disciplinarity and the constant synergistic interaction of all the actors of arthritis care: rheumatologists, radiologists, patients, researchers, regulators, industries and small- and medium sized enterprises (SMEs). On the long term, AutoPiX will create new clinically-validated methods to achieve a/ more precise, accessible and effective diagnosis, b/ shortened and better-tailored treatment paths and c/ improved treatment response assessments and outcome prediction for patients with arthritis.
Funded Companies:
| Company name | Funding amount |
| CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS | ? |
| Ages - Osterreichische Agentur FUR Gesundheit UND Ernahrungssicherheit GmbH | €250,625 |
| CHARITE - UNIVERSITAETSMEDIZIN BERLIN | €505,000 |
| Collective Minds Radiology AB | €1,669,500 |
| EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GmbH | €699,875 |
| Instituto de Salud Musculoesqueletica SL | €423,186 |
| Janssen Pharmaceutica N.V. | €0.00 |
| Medizinische Universitaet Wien | €2,804,289 |
| MOONLAKE IMMUNOTHERAPEUTICS AG | €0.00 |
| NOVARTIS PHARMA AG | €0.00 |
| Queen Mary University of London | €235,288 |
| Region Hovedstaden | €499,686 |
| Ropca ApS | €500,417 |
| RUHR-UNIVERSITAET BOCHUM | €2,607,188 |
| Scienta LAB | €330,875 |
| Singularity Biomed SL | €203,500 |
| UCB Biopharma | €0.00 |
Source: https://cordis.europa.eu/project/id/101194766
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
The visualizations for "CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS - EU funding (€10.7M): IMAGING FOR PATIENT BENEFIT IN ARTHRITIS"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
